Finance

Lists
NONOF:OTCMKTS
Novo Nordisk A/S
၃၈.၁၅ US$
-၀.၃၄%
(-၀.၁၃) 1D
အောက် ၉, GMT-၄ ၁၆:၀၀:၀၀  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NONOF...
Open
၃၈.၂၈ US$
High
၃၈.၅၈ US$
Low
၃၅.၆၃ US$
Mkt. cap
ဋေ ၁.၂၈ သ
Avg. vol.
၁.၁၇ သိန်း
Volume
၄.၂၅ သိန်း
52-wk high
၆၄.၇၅ US$
52-wk low
၃၄.၀၀ US$
Beta
၀.၆၃
Shares outstanding
၃၃၉.၀၁ ဋေ
No. of employees
၇ သောင်း
Open
၃၈.၂၈ US$
High
၃၈.၅၈ US$
Low
၃၅.၆၃ US$
Mkt. cap
ဋေ ၁.၂၈ သ
Avg. vol.
၁.၁၇ သိန်း
Volume
၄.၂၅ သိန်း
52-wk high
၆၄.၇၅ US$
52-wk low
၃၄.၀၀ US$
Beta
၀.၆၃
Shares outstanding
၃၃၉.၀၁ ဋေ
No. of employees
၇ သောင်း
News stories
From web sources and news partners
AD HOC NEWS
AD HOC NEWS
·
ပြီးခဲ့သည့် ၃ နာရီ
Novo Nordisk stock gains 3.52 percent for the week to EUR 34.39
Simply Wall Street
Simply Wall Street
·
ပြီးခဲ့သည့် ၁၁ နာရီ
Novo Nordisk (NVO) Stock May Trade Below Fair Value After GLP 1 Expansion Plans
Traders Union
Traders Union
·
ပြီးခဲ့သည့် ၁ ရက်
Novo Nordisk stock support test at $37.43: Technical outlook
Investing.com
Investing.com
·
ပြီးခဲ့သည့် ၁ ရက်
Novo Nordisk stock target cut at Citi on lack of margin growth
Profile
Novo is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s. Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares. Novo is a full member of the European Federation of Pharmaceutical Industries and Associations. The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark's domestic economy, and it became the highest valued company in Europe. Wikipedia
About Novo Nordisk A/S
CEOMaziar Mike Doustdar
Employees၆.၆၇ သောင်း
Founded၁၉၂၃ ဒီ ၂၁
HeadquartersBagsværd, Capital Region of Denmark, ဒိန်းမတ်
Sector-
Previous reportsAll values in DKK
Loading Previous Earnings...
Revenue
Net income
All values in DKK
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
ဋေ ၇.၅၀ ထ
ဋေ ၇.၉၁ ထ
ဋေ ၉.၆၈ ထ
ဋေ ၇.၈၅ ထ
Cost of goods sold
ဋေ ၁.၄၅ ထ
ဋေ ၁.၄၂ ထ
ဋေ ၁.၃၆ ထ
ဋေ ၁.၇၁ ထ
Cost of revenue
ဋေ ၁.၄၅ ထ
ဋေ ၁.၄၂ ထ
ဋေ ၁.၃၆ ထ
ဋေ ၁.၇၁ ထ
Research and development expenses
ဋေ ၁.၁၅ ထ
ဋေ ၁.၂၇ ထ
ဋေ ၁.၀၃ ထ
ဋေ ၁.၁၅ ထ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
ဋေ ၁.၅၈ ထ
ဋေ ၁.၇၁ ထ
ဋေ ၁.၃၂ ထ
ဋေ ၁.၆၃ ထ
Operating expense
ဋေ ၂.၇၃ ထ
ဋေ ၂.၉၇ ထ
ဋေ ၂.၃၆ ထ
ဋေ ၂.၈၀ ထ
Total operating expenses
ဋေ ၄.၁၇ ထ
ဋေ ၄.၃၉ ထ
ဋေ ၃.၇၂ ထ
ဋေ ၄.၅၁ ထ
Operating income
ဋေ ၃.၃၃ ထ
ဋေ ၃.၅၂ ထ
ဋေ ၅.၉၆ ထ
ဋေ ၃.၃၄ ထ
Other non operating income
၁၅၂.၈၀ ဋေ
-၂၄.၁၀ ကုဋေ
-
-
EBT including unusual items
ဋေ ၂.၅၅ ထ
ဋေ ၃.၄၂ ထ
ဋေ ၆.၂၂ ထ
ဋေ ၂.၆၉ ထ
EBT excluding unusual items
ဋေ ၃.၅၁ ထ
ဋေ ၃.၇၆ ထ
ဋေ ၆.၂၂ ထ
ဋေ ၃.၃၂ ထ
Income tax expense
၅၅၁.၁၀ ဋေ
၇၂၉.၄၀ ဋေ
ဋေ ၁.၃၆ ထ
၅၈၈.၆၀ ဋေ
Effective tax rate
၂၁.၆၀%
၂၁.၃၄%
၂၁.၉၀%
၂၁.၉၀%
Other operating expenses
-
-၈.၁၀ ကုဋေ
၁၀.၆၀ ကုဋေ
၂၃.၄၀ ကုဋေ
Net income
ဋေ ၂.၀၀ ထ
ဋေ ၂.၆၉ ထ
ဋေ ၄.၈၆ ထ
ဋေ ၂.၁၀ ထ
Net profit margin
၂၆.၆၈%
၃၃.၉၈%
၅၀.၁၅%
၂၆.၇၄%
Earnings per share
၄.၅၀
၆.၀၄
၆.၆၃
၆.၁၈
Interest and investment income
၃၀.၇၀ ကုဋေ
၄၄၀.၆၀ ဋေ
-
၁၃၁.၄၀ ဋေ
Interest expense
-
-၄၉၆.၆၀ ဋေ
-
-၁၅၀.၀၀ ဋေ
Net interest expenses
၃၀.၇၀ ကုဋေ
-၅၆.၀၀ ကုဋေ
-
-၁၈.၆၀ ကုဋေ
Depreciation and amortization charges
-
-
-
-
EBITDA
ဋေ ၃.၆၅ ထ
ဋေ ၃.၆၇ ထ
ဋေ ၆.၃၁ ထ
ဋေ ၃.၇၀ ထ
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google အက်ပ်များ